1380650-55-4

Upstream product

• 64-17-5 ethanol 
• 93022-07-2 1-(biphenyl-4-yl)cyclopropanecarboxylic acid 
• 31603-77-7 4-biphenylacetonitrile 
• 92855-14-6 1-(biphenyl-4-yl)cyclopropanecarbonitrile 
• 14062-23-8 4-biphenylylacetic acid ethyl ester 

Downstream Products

• 1380650-56-5 1-(4'-acetylbiphenyl-4-yl)cyclopropanecarboxylic acid ethyl ester 
• 1257213-50-5 (R)-1-(4'-(3-methyl-4-(((1-phenylethoxy)carbonyl)amino)isoxazol-5-yl)-[1,1'-biphenyl]-4-yl)cyclopropane-1-carboxylic acid 
• 1380650-58-7 4'-(1-(ethoxycarbonyl)cyclopropyl)biphenyl-4-carboxylic acid 
• 1380650-61-2 ethyl 1-(4'-(2-(benzyloxycarbonyl)-3-(methylamino)but-2-enoyl)biphenyl-4-yl)cyclopropanecarboxylate 
• 1380650-62-3 benzyl 5-(4'-(1-(ethoxycarbonyl)cyclopropyl)biphenyl-4-yl)-3-methylisoxazole-4-carboxylate 
• 1257214-10-0 5-(4'-(1-(ethoxycarbonyl)cyclopropyl)-[1,1'-biphenyl]-4-yl)-3-methylisoxazole-4-carboxylic acid 
• 1380650-63-4 1-{4'-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester 
• 1380650-53-2 1-{4'-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid sodium salt 

Relevant academic research and scientific papers

Efficient cyclopropanation of aryl/heteroaryl acetates and acetonitriles with vinyl diphenyl sulfonium triflate

A convenient method was developed for the cyclopropanation of aryl acetates and aryl acetonitrile using vinyl diphenyl sulfonium triflate salt. The newly developed conditions are simple, mild, and compatible with a wide range of functional groups, without the need to apply an inert atmosphere, or alkali bases.

POLYCYCLIC LPA1 ANTAGONIST AND USES THEREOF

Described herein is the LPA1 antagonist 1- {4'-[3-methyl-4-((R)- l-phenyl-ethoxycarbonylamino)- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1), or pharmaceutically acceptable salts thereof. Also described are methods of preparing t

POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS

Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.